image

SEC Filing Details

We are focused on the rapid design and development of new medicines based on breakthroughs in cancer research.
SEC Filing Details

Document Details

Form
Filing Date
December 01, 2021
Document Date
November 29, 2021
Form Description
Initial filing by director officer or owner of more than ten percent.
Filing Group
3,4,5
Company
Prelude Therapeutics
Issuer
PRELUDE THERAPEUTICS INC
Filer
Chardonnet Laurent